Business Context and Reporting Period
Company: Drugs Made In America Acquisition Corp. (DMAA)
Reporting Period: Fiscal year ended December 31, 2024 (Inception: May 23, 2024)
Business Type: Special Purpose Acquisition Company (SPAC) incorporated in the Cayman Islands.
Objective: To effect a merger, share exchange, or asset acquisition with one or more businesses, specifically targeting the pharmaceutical sector to address U.S. supply chain resilience and drug shortages.
Status: As of December 31, 2024, the Company had no operations and no revenue. The Initial Public Offering (IPO) was consummated on January 29, 2025, with the over-allotment option exercised on February 18, 2025.
Key Financial Metrics
| Metric | Value (as of Dec 31, 2024) | Value (Post-IPO/Over-Allotment) |
|---|---|---|
| Revenue | $0 | $0 (No operations) |
| Net Loss | $(279,845) | N/A |
| Cash on Hand | $1,351 | $231,150,000 (in Trust Account) |
| Total Assets | $550,824 | N/A |
| Total Liabilities | $795,669 | N/A |
| Shareholders' Deficit | $(244,845) | N/A |
| Trust Account Balance | $0 | $231,150,000 ($10.05 per public share) |
| Deferred Underwriting Fees | $0 | $6,900,000 |
Material Changes and Subsequent Events
The financial statements reflect the pre-IPO period. Significant capital events occurred subsequent to the reporting date:
- Initial Public Offering (Jan 29, 2025): Sold 20,000,000 Units at $10.00 per unit, generating $200,000,000 in gross proceeds.
- Private Placement (Jan 29, 2025): Sponsor purchased 400,000 Private Placement Units for $4,000,000.
- Over-Allotment Exercise (Feb 18, 2025): Underwriters exercised the full option for 3,000,000 additional Units, generating $30,000,000. Sponsor purchased an additional 30,000 Private Placement Units for $300,000.
- Trust Account Funding: A total of $231,150,000 was deposited into the Trust Account following the IPO and over-allotment.
- Transaction Costs: Total transaction costs amounted to $8,898,201, including $1,150,000 in cash underwriting fees and $6,900,000 in deferred fees.
Outlook, Risks, and Management Commentary
Business Combination Timeline: The Company has 15 months from the IPO closing (January 29, 2025) to complete an initial business combination. This period may be extended twice by three months each (total 21 months) if the Sponsor deposits $0.10 per public share into the Trust Account.
Liquidity and Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern within one year of the financial statement issuance date due to the mandatory liquidation requirement if a business combination is not completed. No adjustments have been made to the financial statements for this uncertainty.
Internal Controls: The Company identified a material weakness in internal control over financial reporting due to inadequate segregation of duties and insufficient written policies, resulting from limited personnel.
Risk Factors:
- Geopolitical Instability: Ongoing conflicts (Russia-Ukraine, Israel-Hamas) and sanctions could disrupt capital markets and the search for a target.
- Trust Account Claims: While the Sponsor has agreed to indemnify the Trust Account against third-party claims (up to $10.05 per share), there is no guarantee the Sponsor has sufficient assets to satisfy this obligation.
- Redemption Risk: Public shareholders may redeem shares upon the completion of a business combination, potentially reducing funds available for the transaction.
Investor Verification Checklist
- Trust Account Status: Verify the current balance and interest earnings in the Trust Account maintained by Wilmington Trust, National Association.
- Extension Rights: Confirm the Sponsor's financial capacity to fund potential extensions ($0.10 per share) if the 15-month deadline is not met.
- Internal Control Remediation: Review subsequent filings for updates on the remediation of the material weakness in internal controls.
- Target Identification: Monitor for any announcements regarding substantive discussions with potential pharmaceutical acquisition targets.
- Related Party Transactions: Track the utilization of the Subscription Promissory Note (up to $1,100,000) and the $10,000 monthly administrative fee paid to the Sponsor.